Industry Satellite Symposia webcasts

20/10/2023

Astellas Pharma Europe Ltd     
The evolving treatment landscape in LA/mUC

Watch session

• Housekeeping and introductions
  Ignacio Duran Martinez     
• First-line therapy for patients with LA/mUC: The transformation of the treatment landscape and current unmet needs
  Ignacio Duran Martinez
• Overview of current trials investigating first-line treatment of LA/mUC
  Terence Friedlander       
• Clinical experiences with first-line treatment of LA/mUC
  Friederike Schlürmann , Terence Friedlander       
• Panel discussion
  Ignacio Duran Martinez , Friederike Schlürmann , Terence Friedlander   
• Summary and close
  Ignacio Duran Martinez

AstraZeneca     
Evolving Paradigms in Hormone Receptor-Positive Breast Cancer: The Rise of Antibody-Drug Conjugates

Watch session

• Welcome and Introduction
  Javier Cortés       
• Antibody-Drug Conjugates for HR-Positive Breast Cancer: Where Are We Today?
  Peter Fasching
• Next-Generation Antibody-Drug Conjugates in Practice: A Case-Based Discussion
  Sara A. Hurvitz            
• New Antibody-Drug Conjugates on the Horizon
  Peter Schmid            
• Audience Q&A
  All Faculty
• Concluding Remarks
  Javier Cortés

Bayer     
Delivering on the Promise of Precision Oncology: From the Big Bang to Tangible Impact on Patients’ Lives

Watch session

• Welcome
  Vivek Subbiah
• The Voice That Matters - A Patient Perspective
  Vivek Subbiah            
• The Big Bang of Precision Oncology: Creating Milestones in Medicine
  Vivek Subbiah            
• Theory to Reality: Overcoming Challenges and Raising the Value of Precision Oncology
  Vivek Subbiah, Javier Hernandez-Losa            
• Making It Stick: Implementing the Advances in Precision Oncology into Clinical Practice
  Vivek Subbiah, Jarushka Naidoo, Daniel Shao Weng Tan       
• Impact From Within: Patient Advocacy and the Voices That Bring Progress
  Amy Moore       
• Open Panel Audience Q&A
  All Faculty
• Closing Remarks
  Vivek Subbiah

Boehringer Ingelheim
Rethinking Cancer Therapies: Fresh Perspectives on MDM2-p53, HER2, DLL3 and Other Targets in Cancer

Watch session

• Welcome and Introduction of Agenda and Speakers
  Charles M. Rudin
• Restoring p53 by Antagonizing MDM2-p53 in Soft Tissue Sarcoma
  Patrick Schoeffski
• Improving HER2 Targeting in NSCLC with Selective TKI
  Zofia Piotrowska
• T-cell Engagers: Fighting Solid Tumors from Within
  Charles M. Rudin
• Panel Discussion and Audience Q&A, Key Takeaways and Closing Remarks
  All Faculty

Bristol Myers Squibb     
Immuno-Oncology Landscape for GI Cancers: Perspectives on Current Practices and Recent Advances 

Watch session

• Welcome and Introduction
  John A. Bridgewater
• Immunotherapeutic Advances in the Treatment of Esophageal Cancer
  Peter C. Thuss-Patience
• Update on Immuno-Oncology for the Treatment of Gastric Cancer
  Tania C. Fleitas
• Advances in Immuno-Oncology for the Treatment of Colorectal Cancer
  Maria Elena Elez Fernandez
• Roundtable Case Discussion, Q&A
  All Faculty
• Summary and Close
  John A. Bridgewater

Janssen Pharmaceutica N.V.     
Targeted therapy optimising the future of GU cancer care – realising the value, exploring the evidence    

Watch session

• Opening remarks & introduction
  Aurelius G. Omlin, Alison J. Birtle
• How can we balance efficacy and QoL in mHSPC treatment? Why it’s time to tailor treatments
  Friederike Schlürmann, Laura-Maria Krabbe
• Germ line testing and genomic profiling - isn’t it time for personalised prostate cancer care?
  David Olmos, Niven Mehra
• Revolutionising urothelial carcinoma care: Discovering the value of targeted therapy
  Guillermo Antonio De Velasco Oria
• Interactive Q&A session
  All Faculty    
• Closing remarks
  Aurelius G. Omlin, Alison J. Birtle

Seagen     
HER2-Targeted Therapies in mCRC: Are We Ready for a Paradigm Shift?   

Watch session

• Welcome and Introduction
  Salvatore Siena
• HER2 as an Actionable Target in HER2+ mCRC
  Kimmie Ng
• The Role of HER2 Testing in mCRC
  Richard A. Adams
• Exploring New Opportunities to Improve Outcomes in Patients with HER2+ mCRC
  Salvatore Siena
• Panel Discussion and Interactive Q&A
  Salvatore Siena, Kimmie Ng, Richard A. Adams
• Closing Remarks
  Salvatore Siena

Servier     
Are brain cancer patients finally able to benefit from precision medicine approaches? 

Watch session

• Introduction: The Sword of Damocles hanging over each patient
  Carmen Balana
• IDH Mutated Glioma: A Decade’s journey from bench to bedside
  Timothy Cloughesy
• Connecting the dots: Understanding recent clinical evidence in the framework of previous studies and current practice
  Martin J. Van den Bent
• The evolving paradigm for clinical management of glioma
  Sara Erridge
• Navigating the paradigm shift: Thriving in the new era glioma care
  Ghazaleh Tabatabai

Servier     
A journey through IDH1mutated Cholangiocarcinoma - Unveiling clinical and therapeutic perspectives    

Watch session

• Introduction
  Michel P. Ducreux
• Introducing a patient case with IDH1 mutated CCA
  Teresa Macarulla    
• CCA diagnosis: current practice and challenges
  Teresa Macarulla, Erika Martinelli
• Molecular profiling in CCA: where do we stand?
  Teresa Macarulla, Albrecht Stenzinger
• Treatment landscape in CCA and future perspectives
  Benedikt Westphalen, Teresa Macarulla
• Panel discussion Q&A
  All Faculty
• Conclusion
  Michel P. Ducreux

21/10/2023

Gilead Sciences Europe Ltd     
MILLIONS OF LIVES. ONE MISSION. Exploring the potential of ADCs in multiple solid tumours

Watch session

• Welcome and introduction: ADCs – A journey across time
  Peter Schmid
• Improving the lives of patients with triple-negative and HR+/HER2- metastatic breast cancer
  Sara M. Tolaney
• Unlocking the potential for the treatment of metastatic urothelial cancer
  Thomas B. Powles   
• Expanding opportunities in patients with metastatic NSCLC
  Enriqueta Felip   
• Q&A and closing remarks
  All Faculty

Servier     
Shining the light on colorectal cancer: Advancing treatment strategies in mCRC

Watch session

• Introduction
  Eric Van Cutsem  
• New approaches in treating patients with mCRC
  Jenny Seligmann   
• Redefining the meaning of later lines of therapy
  Julien Taieb   
• Patient cases in mCRC and panel discussion
  Fortunato Ciardiello
• Conclusion
  Julien Taieb

22/10/2023

Astellas Pharma Europe Ltd     
Putting the patient first: Considering treatment choice and maximising quality of life in mHSPC

Watch session

• Welcome and introduction
  Christopher Sweeney
• Reinforcing standard of care: The benefits of early treatment intensification in patients with mHSPC
  Heather A. Payne, Christopher Sweeney, Javier Puente
• The importance of first-line treatment choice in patients with mHSPC
  Heather A. Payne, Christopher Sweeney, Javier Puente
• Maximising quality of life: Holistic approaches in the management of patients with mHSPC
  Heather A. Payne, Christopher Sweeney, Javier Puente
• Closing remarks
  Christopher Sweeney

GSK     
The breakthrough era in endometrial cancer treatment

Watch session

• Three ways EC management is changing
  Christian Marth   
• Anti–PD-(L)1s plus chemotherapies continue to evolve: Updates from 2023 congresses
  Ilaria Colombo   
• Synergy: Is it more than a buzzword for IO plus PARPi or TKI?
  Kathleen N. Moore
• Surge in molecular-based targets brings new hope for EC treatment
  Christian Marth, Ilaria Colombo, Kathleen N. Moore
• Full discussion/Q&A
  All Faculty   

Illumina     
Detection of homologous recombination deficiency (HRD): Role of HRD testing and impact on patient management

Watch session

• Introduction & Welcome
  Frederique Penault-Llorca
• The role of HRD and related tests in cancer care
  Frederique Penault-Llorca
• The clinical value of HRD testing in ovarian cancer
  Domenica Lorusso    
• The value of biomarker testing for homologous recombination deficiency in prostate cancer
  David Olmos    
• The utility of HRD testing – current status and future trends
  Frederique Penault-Llorca, Fiona Barve, Domenica Lorusso, David Olmos
• Closing remarks
  Frederique Penault-Llorca

Janssen Pharmaceutica N.V.     
Transforming treatment approaches for patients with EGFR-mutant NSCLC

Watch session

• Welcome and introductions
  Luis Paz-Ares  
• Strategies for overcoming EGFR resistance in NSCLC patient management
  Antonio Passaro   
• Expanding our horizons: Novel frontline approaches in EGFR-mutant NSCLC
  Nicolas Girard   
• Current and future directions for EGFR exon 20 insertion mutations in NSCLC
  Joshua K. Sabari   
• Key learnings/closing remarks
  Natasha Leighl

Seagen     
ADCs’ Potential Across Tumors

Watch session

• Welcome and Introduction
  Josep Tabernero   
• ADC Technologies in Oncology
  Josep Tabernero   
• Emerging ADCs in Non-Small Cell Lung Cancer
  David Planchard   
• Advances in ADCs for Head and Neck Cancer
  Laura D. Locati    
• Future Directions for ADCs in Urothelial Cancer
  Thomas B. Powles   
• Panel Discussion and Audience Q&A
  All Faculty
• Closing Remarks
  Josep Tabernero

23/10/2023

Bristol Myers Squibb     
The Changing Paradigm of Melanoma Treatment: A Clinical Update for 2023

Watch session

• Welcome and Introduction
  Eva Muñoz Couselo  
• Navigating the Adjuvant Setting: Who, When, and What?
  Eva Muñoz Couselo   
• Current and Emerging Neoadjuvant Treatment Options for Resectable Melanoma
  Sapna Patel
• Panel Discussion: Factors Impacting Treatment Selection for Resectable Melanoma
  All Faculty
• Evidence-Based Considerations for the First-Line Treatment of Metastatic Melanoma
  Dirk Schadendorf    
• Summary and Close
  Eva Muñoz Couselo

GSK     
The Need for Better Patient Outcomes: Latest Investigational Approaches for dMMR/MSI-H CRC

Watch session

• Welcome & introduction
  Jenny Seligmann 
• Locally Advanced dMMR/MSI-H Rectal Cancer: New Approaches Under Investigation
  Aparna Parikh   
• Locally Advanced dMMR/MSI-H Colon Cancer: New Approaches Under Investigation
  Volker Heinemann
• The Multidisciplinary Approach to Locally Advanced dMMR/MSI-H CRC: Reducing the Patient Burden
  Jenny Seligmann
• Q&A | Panel Discussion
  All Faculty

Novocure GmbH     
The evolving role of TTFields therapy in solid tumors

Watch session

• Welcome
  Joachim G. Aerts   
• Practice changing experience of TTFields therapy in Glioblastoma
  Stefan Rieken
• Evolving role of TTFields therapy in NSCLC
  Joachim G. Aerts
• Bringing change with TTFields therapy in ovarian cancer
  Jalid Sehouli
• Fireside chat
  All Faculty

Seagen     
Case by Case: Strategic Sequencing Considerations in 3L HER2+ Metastatic Breast Cancer (MBC)

Watch session

• Welcome and Introductions
  Cristina Saura Manich
• Embracing Change: Uncovering Challenges and Opportunities in the Changing Treatment Landscape of HER2+ MBC
  Cristina Saura Manich
• Decision-making in 3L Following T-DXd Progression (Case-based discussion)
  Joyce O'Shaughnessy
• Decision-making in 3L Progression With CNS Involvement (Case-based discussion)
  Michelino De Laurentiis
• Charting the Course: Navigating the Landscape From Real-world Evidence to Future Studies
  Joseph Gligorov
• Q&A
  All Faculty
• Closing Remarks
  Cristina Saura Manich